文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

脓毒症患者使用哌拉西林-他唑巴坦与头孢吡肟的死亡率比较

Mortality of Patients With Sepsis Administered Piperacillin-Tazobactam vs Cefepime.
PubMed 文献 · JAMA Intern Med · 2024-01-01
一句话结论在疑似脓毒症且无明确抗厌氧菌指征的患者中,使用哌拉西林-他唑巴坦与90天死亡率绝对增加5.0%(95%CI 1.9%-8.1%)及器官功能障碍时间延长相关。

该回顾性队列研究纳入密歇根大学2014年7月1日至2018年12月31日收治的7569例疑似脓毒症成人患者,均接受万古霉素联合哌拉西林-他唑巴坦或头孢吡肟治疗,并利用2015年6月12日至2016年9月18日共15个月的哌拉西林-他唑巴坦短缺期作为工具变量进行分析。结果显示,哌拉西林-他唑巴坦组90天死亡率绝对增加5.0%(95%CI 1.9%-8.1%),无器官衰竭天数减少2.1天(95%CI 1.4-2.7),无呼吸机天数减少1.1天(95%CI 0.57-1.62),无血管活性药天数减少1.5天(95%CI 1.01-2.01)。作者认为,在无明确抗厌氧菌指征的疑似脓毒症患者中,广泛经验性使用抗厌氧菌抗生素可能有害。

要点

  • 在疑似脓毒症且无明确抗厌氧菌指征的成人患者中,哌拉西林-他唑巴坦组90天死亡率较头孢吡肟组绝对增加5.0%(95%CI 1.9%-8.1%)。
  • 哌拉西林-他唑巴坦组无器官衰竭天数减少2.1天(95%CI 1.4-2.7),无呼吸机天数减少1.1天(95%CI 0.57-1.62),无血管活性药天数减少1.5天(95%CI 1.01-2.01)。
  • 研究利用15个月哌拉西林-他唑巴坦短缺期作为工具变量,哌拉西林-他唑巴坦组仅152例(3%)在短缺期接受该药。
  • 两组在年龄、Charlson合并症指数评分、序贯器官衰竭评估评分或抗生素给药时间上无显著差异。
  • 作者认为,在无明确抗厌氧菌指征的疑似脓毒症患者中,广泛经验性使用抗厌氧菌抗生素可能有害。

适用人群与场景

  • 成人疑似脓毒症患者,接受万古霉素联合哌拉西林-他唑巴坦或头孢吡肟治疗,且病情在哌拉西林-他唑巴坦与头孢吡肟之间存在推定均衡。
  • 研究场景为密歇根大学医院2014年7月1日至2018年12月31日的住院患者,包含2015年6月12日至2016年9月18日的哌拉西林-他唑巴坦短缺期。

研究设计与关键结果

  • 回顾性队列研究纳入7569例患者(4174例男性[55%];中位年龄63岁[IQR 52-73]),其中4523例接受万古霉素联合哌拉西林-他唑巴坦,3046例接受万古霉素联合头孢吡肟。
  • 哌拉西林-他唑巴坦组仅152例(3%)在短缺期接受该药。
  • 两组在年龄、Charlson合并症指数评分、序贯器官衰竭评估评分或抗生素给药时间上无显著差异。
  • 工具变量分析显示,哌拉西林-他唑巴坦与90天死亡率绝对增加5.0%(95%CI 1.9%-8.1%)相关。
  • 哌拉西林-他唑巴坦组无器官衰竭天数减少2.1天(95%CI 1.4-2.7),无呼吸机天数减少1.1天(95%CI 0.57-1.62),无血管活性药天数减少1.5天(95%CI 1.01-2.01)。

证据类型、等级与局限

  • 证据类型:回顾性队列研究,采用工具变量分析(哌拉西林-他唑巴坦短缺期作为工具变量)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在无明确抗厌氧菌指征的疑似脓毒症患者中,广泛经验性使用抗厌氧菌抗生素可能有害。
  • 研究结果提示,对于疑似脓毒症且无明确抗厌氧菌覆盖指征的患者,使用哌拉西林-他唑巴坦与头孢吡肟相比,90天死亡率更高且器官功能障碍持续时间更长。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Experimental and observational studies have suggested that empirical treatment for bacterial sepsis with antianaerobic antibiotics (eg, piperacillin-tazobactam) is associated with adverse outcomes compared with anaerobe-sparing antibiotics (eg, cefepime). However, a recent pragmatic clinical trial of piperacillin-tazobactam and cefepime showed no difference in short-term outcomes at 14 days. Further studies are needed to help clarify the empirical use of these agents.

OBJECTIVE: To examine the use of piperacillin-tazobactam compared with cefepime in 90-day mortality in patients treated empirically for sepsis, using instrumental variable analysis of a 15-month piperacillin-tazobactam shortage.

DESIGN, SETTING, AND PARTICIPANTS: In a retrospective cohort study, hospital admissions at the University of Michigan from July 1, 2014, to December 31, 2018, including a piperacillin-tazobactam shortage period from June 12, 2015, to September 18, 2016, were examined. Adult patients with suspected sepsis treated with vancomycin and either piperacillin-tazobactam or cefepime for conditions with presumed equipoise between piperacillin-tazobactam and cefepime were included in the study. Data analysis was conducted from December 17, 2022, to April 11, 2023.

MAIN OUTCOMES AND MEASURES: The primary outcome was 90-day mortality. Secondary outcomes included organ failure-free, ventilator-free, and vasopressor-free days. The 15-month piperacillin-tazobactam shortage period was used as an instrumental variable for unmeasured confounding in antibiotic selection.

RESULTS: Among 7569 patients (4174 men [55%]; median age, 63 [IQR 52-73] years) with sepsis meeting study eligibility, 4523 were treated with vancomycin and piperacillin-tazobactam and 3046 were treated with vancomycin and cefepime. Of patients who received piperacillin-tazobactam, only 152 (3%) received it during the shortage. Treatment groups did not differ significantly in age, Charlson Comorbidity Index score, Sequential Organ Failure Assessment score, or time to antibiotic administration. In an instrumental variable analysis, piperacillin-tazobactam was associated with an absolute mortality increase of 5.0% at 90 days (95% CI, 1.9%-8.1%) and 2.1 (95% CI, 1.4-2.7) fewer organ failure-free days, 1.1 (95% CI, 0.57-1.62) fewer ventilator-free days, and 1.5 (95% CI, 1.01-2.01) fewer vasopressor-free days.

CONCLUSIONS AND RELEVANCE: Among patients with suspected sepsis and no clear indication for antianaerobic coverage, administration of piperacillin-tazobactam was associated with higher mortality and increased duration of organ dysfunction compared with cefepime. These findings suggest that the widespread use of empirical antianaerobic antibiotics in sepsis may be harmful.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Chanderraj R, Admon AJ, He Y, et al. Mortality of Patients With Sepsis Administered Piperacillin-Tazobactam vs Cefepime. JAMA Intern Med. 2024. PMID: 38739397. doi:10.1001/jamainternmed.2024.0581

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。